The Record - for physicians and other health care providers to share with their office staffs Forward to a friend  |  Subscribe  |  The Record Archive  |  Contacts  |  bcbsm.com  |  Print this article
April 2015

HCPCS procedure code Q9975 replaces J7199 when billing for Eloctate™

Effective April 1, 2015, the Centers for Medicare & Medicaid Services has established a permanent procedure code for Eloctate, which is an antihemophilic (recombinant), Fc fusion protein.

That means that for services that occurred through March 31, 2015, you should continue to report code J7199. For services that take place on or after April 1, 2015, you should use the replacement code of Q9975.

Eloctate is a recombinant DNA derived, antihemophilic factor found in adults and children with hemophilia A, or congenital factor VIII deficiency, and is used for:

  • Control and prevention of bleeding episodes
  • Perioperative management (surgical prophylaxis)
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes

Note: Eloctate is not indicated for the treatment of von Willebrand disease.

No portion of this publication may be copied without the express written permission of Blue Cross Blue Shield of Michigan, except that BCBSM participating health care providers may make copies for their personal use. In no event may any portion of this publication be copied or reprinted and used for commercial purposes by any party other than BCBSM.

*CPT codes, descriptions and two-digit numeric modifiers only are copyright 2014 American Medical Association. All rights reserved.
Blue Cross Blue Shield of Michigan and Blue Care Network are nonprofit corporations and
independent licensees of the Blue Cross and Blue Shield Association.